StageAcquired | Acquired
About Imthera Medical
ImThera Medical is an early stage company developing a novel, patent pending neurostimulation medical device for the treatment of Obstructive Sleep Apnea (OSA). ImThera's Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy delivers neurostimulation to the tongue during sleep. Using a multi-contact electrode and a programmable pulse generator, the system delivers muscle tone to key tongue muscles, effectively controlling upper airway flow and reducing or eliminating sleep apnea.
Missing: Imthera Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Imthera Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Imthera Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Imthera Medical is included in 4 Expert Collections, including Sleep Health & Wellness.
Sleep Health & Wellness
These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Imthera Medical Patents
Imthera Medical has filed 26 patents.
The 3 most popular patent topics include:
- Sleep disorders
- Abnormal respiration
- Human head and neck
Sleep disorders, Neurotechnology, Implants (medicine), Medical terminology, Neurophysiology
Sleep disorders, Neurotechnology, Implants (medicine), Medical terminology, Neurophysiology
Latest Imthera Medical News
Aug 4, 2022
By Reading Time: 5 minutes Acumen Research and Consulting recently published report titled “Neurostimulation Devices Market Size, Share, Analysis Report and Region Forecast, 2022 – 2030” LOS ANGELES, Aug. 04, 2022 (GLOBE NEWSWIRE) — The Global Neurostimulation Devices Market size is valued at USD 6,141 million in 2021 and is estimated to achieve a market size of USD 15,994 million by 2030; growing at a CAGR of 11.3%. The rising prevalence of neurological disorders is driving the global neurostimulation devices market revenue. Neurological disorders affect up to one billion people worldwide, according to a World Health Organization (WHO) report. Alzheimer’s disease, multiple sclerosis, brain injuries, neuro infections, and Parkinson’s disease are examples of neurological disorders. According to the same report, neurological disorders can affect people of any age, gender, or income. According to the Neurological Disorders – Public Health Challenges study, approximately 6.8 million people die each year as a result of neurological disorders. The diagnosis of neurological disorders is a widespread concern and one of modern medicine’s most difficult challenges. As a result, growing technological advancements and rising R&D activities are two key neurostimulation devices market trends driving industry demand. Request For Free Sample Report @ USD 6,141 Million USD 15,994 Million Analysis Period Regional Scope Key Companies Profiled Boston Scientific Corporation, Medtronic, St. Jude Medical, Bayer AG, Cyberonics, Inc, IntraPace Inc., Neuronetics, Nevro Corp., Uroplasty, Inc., ImThera Medical, Inc., and NeuroPace, Inc. Report Coverage COVID-19 Impact on the Global Neurostimulation Devices Market Value The neurostimulation device industry is slightly affected by the COVID-19 pandemic. Because of the imposed lockdowns, reduced manufacturing, and disrupted supply chain, this occurred. Additionally, a lack of workforce and a slowed distribution network of many companies hampered industry growth. However, the gradual removal of lockdowns and the resumption of manufacturing and sales boosted the neurostimulation devices market share beginning in 2021. Despite this, the industry did not recover quickly due to a drop in the treatment of non-covid-19 emergency procedures. Neurostimulation Devices Market Dynamics The increasing prevalence of lifestyle disorders such as chronic pain and depression, as well as the increase in the number of neurological disorders, are the primary factors driving the neurostimulation devices market share. The growing elderly population, combined with the rising prevalence of chronic diseases, is driving the demand for neurostimulation devices. Additionally, rising demand for minimally invasive surgeries is expected to drive market demand. However, neurostimulation devices can cause complications in the human body, limiting the market growth. As a result, strict regulatory frameworks are imposed on these devices, resulting in a time-consuming approval process by global health and regulatory organizations. This factor is once again preventing the market from expanding. The growing burden of several neurological and chronic disorders fuels the neurostimulation devices market share Neurological disorders are becoming more widely recognized as major causes of death and disability around the world. According to data from Neurological Disorders: Public Health Challenges, 50 million people with epilepsy and 24 million with Alzheimer’s or other dementias are among the 1 billion people diagnosed with neurological disorders. According to a systematic analysis conducted for the Global Burden of Disease Study, neurological diseases are the leading cause of disability-adjusted life years (DALYs), or years of healthy life lost due to death or disability. Neurological disorders caused 250.7 million disability-adjusted life years (DALYs) in 2015, a rise of 7.4 percent from 1990, with stroke included for the first time in such a broad and thorough study. Check the detailed table of contents of the report @ The global market is divided into four segments: product, application, end-use, and region. Based on products, the market is segregated into vagus nerve stimulators, deep brain stimulators, gastric electric stimulators, sacral nerve stimulators, and spinal cord stimulators. According to our neurostimulation devices industry analysis, spinal cord stimulators gathered a dominant market share between 2022 and 2030. However, the deep brain stimulators sub-segment is anticipated to register the fastest growth rate during the forecast timeframe from 2022 to 2030. The application segment includes depression, dystonia, epilepsy, essential tremor, gastroparesis, pain management, Parkinson’s disease, urinary & fecal incontinence, and others. Pain management held a noteworthy market share in 2021, whereas epilepsy is expected to grow rapidly during the forecasted years. Furthermore, hospitals and specialty clinics are covered under the end-use segment. In 2021, hospitals acquired a noteworthy market share and are expected to continue during the forecast period. In terms of growth, specialty clinics will grow at a notable rate in the coming years. Neurostimulation Devices Market Regional Outlook The global neurostimulation devices market is divided into five regions: North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. According to the global neurostimulation devices market forecast, North America held the majority of the share in 2021 and will continue its dominance henceforth. Recent data published by the Hearing Health Foundation suggest that over 48 million Americans are affected by neurological disorders. According to the CDC, more than 50% of elderly Americans experienced bowel or urinary leakage in 2014. All these statistics are paving a way for the growth of the North America neurostimulation devices market In terms of growth, the Asia-Pacific region is likely to register a substantial CAGR owing to the increasing awareness related to neurological disorders. Additionally, growing government initiatives, rising research & development activities, and improving healthcare infrastructure are some of the aspects that are driving the Asia-Pacific neurostimulation devices market. Buy this premium research report – Neurostimulation Devices Market Players Some prominent neurostimulation devices companies covered in the industry are Bayer AG, Boston Scientific Corporation, Cyberonics, Inc, ImThera Medical, Inc., IntraPace Inc., Medtronic, NeuroPace, Inc., Neuronetics, Nevro Corp., St. Jude Medical, and Uroplasty, Inc. Browse More Research Topic on Medical Sector: The Global Lacrimal Devices Market accounted for USD 137 Million in 2020 and is expected to reach USD 185 Million by 2028 with a considerable CAGR of 3.9% during the forecast timeframe of 2021 to 2028. The Global Blood Pressure Monitoring Devices Market accounted for revenue of USD 1.6 Billion in 2020 with a considerable CAGR of 11.4% during the analysis period of 2021 to 2028. The Global Anastomosis Devices Market accounted for USD 2,219 Million in 2020 and is expected to reach USD 3,822 Million by 2028 with a considerable CAGR of 7.1% during the forecast period of 2021 to 2028. Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise. For Latest Update Follow Us on Twitter and, LinkedIn Contact Us:
Imthera Medical Frequently Asked Questions (FAQ)
When was Imthera Medical founded?
Imthera Medical was founded in 2004.
Where is Imthera Medical's headquarters?
Imthera Medical's headquarters is located at 12555 High Bluff Drive, San Diego.
What is Imthera Medical's latest funding round?
Imthera Medical's latest funding round is Acquired.
How much did Imthera Medical raise?
Imthera Medical raised a total of $19.07M.
Who are the investors of Imthera Medical?
Investors of Imthera Medical include LivaNova, Cyberonics, Augment Securities and Qualifying Therapeutic Discovery Project.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.